Ten post jest także dostępny w języku: polski
PZU Zdrowie does not slow down. After the acquisition of Falck outpatient clinics, PZU wants to take over Tomma’s network of imaging diagnostics clinics in Poland. The seller is the Tar Heel Capital fund, of which we informed earlier.
PZU submitted an application to UOKiK
Still in July, Tar Heel Capital announced that it would be thinking about leaving the investment at the earliest in 2020. (we have written more about it here). From the very beginning it was known that Tomma Diagnostyka Obrazowa will be an attractive morsel for both professional and financial investors. Now it turns out that the race was won by PZU Zdrowie, which has just submitted an application to the Office of Competition and Consumer Protection (UOKiK) to take control of the company.
Bonus-Diagnosta and Asklepios Diagnostyka are to be taken over together with Tomma Diagnostyka Obrazowa. PZU Zdrowie wants to acquire 100% of shares in all companies.
Good prospects for imaging diagnostics
Tomma Diagnostyka Obrazowa is one of the largest providers of imaging diagnostics services in Poland. Currently, it runs diagnostic laboratories in 32 locations. The segment is prospective. According to PMR data, in 2018-2023 the average annual growth rate (CAGR) may reach almost 6%. However, it is worth noting that the segment of cost-intensive research, such as magnetic resonance imaging, computed tomography and nuclear medicine research, is highly dependent on the financing of the National Health Fund (NFZ).
However, private spending, both FFS and medical subscriptions/private health insurance, is also a factor in market development. In this segment, growth will be driven by strong household consumption, supported by good labour market conditions.
According to Puls Biznesu, PZU will present more details about the transaction next week, during the presentation of its quarterly results.